MyFinsight
Home
Blog
About
Deferred revenue
$52,162K
(457.23%↑ Y/Y)
Proceeds from marketable
securities
$149,755K
(-50.65%↓ Y/Y)
Proceeds from deferred
government contributions...
$13,585K
Stock-based compensation
$12,286K
(-57.62%↓ Y/Y)
Research fees and grants
receivable
-$12,264K
(-197.92%↓ Y/Y)
Depreciation of property and
equipment
$6,059K
(-32.31%↓ Y/Y)
something is missing
$4,970K
Other
-$4,642K
(-795.95%↓ Y/Y)
Other assets
-$3,579K
(73.39%↑ Y/Y)
Amortization of operating
lease right-of-use...
$1,793K
(-37.37%↓ Y/Y)
Amortization of intangible
assets
$931K
(-49.70%↓ Y/Y)
Receipt of grant funding
$5,594K
(-13.24%↓ Y/Y)
Net cash used in
operating activities
$25,923K
(158.97%↑ Y/Y)
Net cash used in
investing activities
$11,341K
(147.50%↑ Y/Y)
Net cash provided by
financing activities
$6,393K
(146.36%↑ Y/Y)
Canceled cashflow
$72,763K
Canceled cashflow
$144,008K
Canceled cashflow
$7,192K
Decrease in cash and cash
equivalents
$43,227K
(167.66%↑ Y/Y)
Canceled cashflow
$430K
Net loss
-$55,427K
(31.02%↑ Y/Y)
Income taxes
receivable
$8,024K
(205.75%↑ Y/Y)
Accounts payable and
accrued liabilities
-$7,215K
(1.92%↑ Y/Y)
Deferred grant income
$2,097K
(24.75%↑ Y/Y)
Purchase of marketable
securities
$141,876K
(-51.34%↓ Y/Y)
Purchases of property and
equipment
$2,132K
(-91.12%↓ Y/Y)
something is missing
-$7,192K
Effect of exchange rate
changes on cash and cash...
-$430K
(-131.83%↓ Y/Y)
Back
Back
Cash Flow
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)
source: myfinsight.com